Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

The user shared positive results after using 5% minoxidil foam nightly and dermastamping weekly for hair growth, noting significant progress after three months. They plan to add finasteride in the future but are currently avoiding it due to age.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

The user underwent a biopsy two years ago and was diagnosed with keratosis pilaris, leading to hair issues. They tried treatments including Minoxidil, betamethasone, lymecycline, topical Accutane, and dutasteride, as well as diet changes, without improvement in hair thickness or skin dryness.

The user is experiencing hair regrowth using daily 5% minoxidil and weekly microneedling, and plans to add finasteride soon. They are considering the effectiveness of once-daily minoxidil and adjusting microneedling needle size.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The conversation is about a user concerned about a prescribed 5 mL daily dose of 5% minoxidil for seborrheic dermatitis and hair thinning, which seems excessive compared to the typical 2 mL recommendation. The user is advised to consult their dermatologist and consider additional treatments like ketoconazole and CBD+MCT.

The user has been using oral finasteride and minoxidil nightly, dutasteride twice a week, microneedling weekly, and pyripure nightly since April. They are seeking opinions on their hair regrowth progress, noting no slick bald areas but some miniaturized blonde hairs.

Tretinoin can irritate seborrheic dermatitis, but using it with a moisturizer on calm skin may help. Parallel Health's skin microbiome testing and phage therapy are suggested for persistent issues.

Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

The user is looking for a PG-free solvent in the UK or EU to make their own pyrilutamide solution for hair loss and is currently using finasteride, considering minoxidil. They hope pyrilutamide will help stabilize their hair loss.

This user has had success with Minoxidil foam, achieving significant hair growth in three months without using finasteride or derma rolling. They are considering incorporating a DHT reducing strategy such as finasteride in the future.

Mixing minoxidil and stemoxydine is not recommended due to potential dilution and reduced effectiveness. Applying them separately with a time gap is suggested.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The user shared a 3-month update on using a 5% minoxidil and finasteride topical solution enriched with redensyl and procapil for hair regrowth. They mentioned inconsistency in using the treatment and initially starting it without consulting a dermatologist.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.

Hair loss treatment with Pyrilutamide, Minoxidil, and Finasteride showed improvement after 4 months. Shedding reduced, hair feels stronger and healthier, with no side effects.

User's 2-month hair loss treatment includes Dut 0.5mg, oral min 2.5mg, Dut+PRP mesotherapy, microneedling, and other products. Dermatologist increased min dose to 5mg, expecting better results at 6-month mark.

The conversation discusses using Actifolic tretinoin to enhance the absorption of Minoxidil for hair loss treatment. It questions the amount of tretinoin to use and whether to apply it before or after Minoxidil.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Adapalene can be used instead of tretinoin for minoxidil absorption, but it is not as strong. Tretinoin is a more potent retinoid.

The user experienced eyebrow hair loss after COVID-19 and has not seen regrowth despite using Latisse. They are seeking new treatment options but are cautious about spending money on ineffective solutions.

User on 5th week of Pyrilutamide and oral Minoxidil, no hair loss improvement yet. Others suggest waiting 3 months for results.